New hope for advanced bladder cancer: experimental combos tested
NCT ID NCT07232602
First seen Nov 18, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This study tests whether adding new investigational drugs to the standard two-drug treatment (enfortumab vedotin plus pembrolizumab) can shrink tumors more safely in people with advanced bladder cancer that has spread. About 55 adults who have not had prior treatment for their advanced cancer will receive the standard therapy plus an extra experimental agent. The main goals are to check side effects and see how many patients' tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center ( Site 5901)
RECRUITINGSeoul, 05505, South Korea
Contact Phone: •••-•••-••••
-
CHU de Bordeaux Hop St ANDRE ( Site 5607)
RECRUITINGBordeaux, Gironde, 33075, France
Contact Phone: •••-•••-••••
-
Cleveland Clinic Taussig Cancer ( Site 5036)
RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-••••
-
Erasmus MC ( Site 5303)
RECRUITINGRotterdam, South Holland, 3015 GD, Netherlands
Contact Phone: •••-•••-••••
-
FALP ( Site 5151)
RECRUITINGSantiago, Region M. de Santiago, 7500921, Chile
Contact Phone: •••-•••-••••
-
Hospital Clinico San Carlos ( Site 5765)
RECRUITINGMadrid, 28040, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitari Vall de Hebron ( Site 5767)
RECRUITINGBarcelona, 08035, Spain
Contact Phone: •••-•••-••••
-
Huntsman Cancer Institute ( Site 5041)
RECRUITINGSalt Lake City, Utah, 84112-5550, United States
Contact Phone: •••-•••-••••
-
Rabin Medical Center ( Site 5504)
RECRUITINGPetah Tikva, 4941492, Israel
Contact Phone: •••-•••-••••
-
Rambam Health Care Campus ( Site 5501)
RECRUITINGHaifa, 3109601, Israel
Contact Phone: •••-•••-••••
-
Samsung Medical Center ( Site 5902)
RECRUITINGSeoul, 06351, South Korea
Contact Phone: •••-•••-••••
-
Severance Hospital, Yonsei University Health System ( Site 5903)
RECRUITINGSeoul, 03722, South Korea
Contact Phone: •••-•••-••••
-
St Bartholomew s Hospital ( Site 5206)
RECRUITINGLondon, London, City of, EC1A 7BE, United Kingdom
Contact Phone: •••-•••-••••
-
UCSF Medical Center at Mission Bay ( Site 5044)
RECRUITINGSan Francisco, California, 94158, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.